PGR

Progesterone receptor · P06401 · PGR on Sugi Atlas →

494,014 patent compounds predicted against PGR, 329,760 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Onapristone Onapristone (SCHEMBL8740) 1.00 13/20
Clocortolone Pivalate Clocortolone Pivalate (SCHEMBL5120) 1.00 10/20
Mifepristone Mifepristone (SCHEMBL16087) 1.00 10/20
SCHEMBL8133 SCHEMBL8133 0.55 10/20
Fluocortolone Fluocortolone (SCHEMBL4644) 0.70 9/20
Fluocortolone Fluocortolone (SCHEMBL8134) 0.65 9/20
Diflucortolone Diflucortolone (SCHEMBL3794) 1.00 8/20
Diflucortolone Diflucortolone (SCHEMBL3795) 1.00 8/20
Diflucortolone Diflucortolone (SCHEMBL3796) 1.00 8/20
Prednicarbate Prednicarbate (SCHEMBL3941) 1.00 8/20
Prednicarbate Prednicarbate (SCHEMBL3942) 1.00 8/20
Alclometasone Dipropionate Alclometasone Dipropionate (SCHEMBL6833) 1.00 8/20
Paramethasone Acetate Paramethasone Acetate (SCHEMBL7126) 0.79 8/20
Methylprednisolone Aceponate Methylprednisolone Aceponate (SCHEMBL3466) 0.74 8/20
Diflucortolone 21-Valerate Diflucortolone 21-Valerate (SCHEMBL3015) 0.73 8/20
Diflucortolone 21-Valerate Diflucortolone 21-Valerate (SCHEMBL13157) 0.73 8/20
Diflucortolone 21-Valerate Diflucortolone 21-Valerate (SCHEMBL13158) 0.73 8/20
SCHEMBL20554 SCHEMBL20554 0.58 8/20
Ciclesonide Ciclesonide (SCHEMBL3688) 1.00 7/20
Deflazacort Deflazacort (SCHEMBL4018) 1.00 7/20

Clinical trials — most relevant to PGR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer PHASE3COMPLETED
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency PHASE3UNKNOWN
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D PHASE3COMPLETED
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive PHASE3COMPLETED
Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women PHASE3COMPLETED
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy PHASE2ACTIVE_NOT_RECRUITING
Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer PHASE2COMPLETED
TRial on the Endocrine Activity of Neoadjuvant Degarelix PHASE2COMPLETED
Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer PHASE2COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer PHASE2UNKNOWN
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) PHASE2NOT_YET_RECRUITING
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer PHASE2COMPLETED
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer PHASE2COMPLETED
A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer PHASE2WITHDRAWN
A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer PHASE2WITHDRAWN
Faslodex 500mg Multiple Dose Tolerability Study in BC Patients PHASE1COMPLETED
A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) PHASE1COMPLETED
Locoregional Recurrence of Breast Cancer nanNOT_YET_RECRUITING
PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women nanRECRUITING
Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients, nanRECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Concordance Between Liquid and Tissue Biopsy nanUNKNOWN
Uterine Cavity Assessment and Endometrial Hormonal Receptors in Women With Peri and Post Menopausal Bleeding nanCOMPLETED
Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status nanCOMPLETED
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions nanUNKNOWN
21-gene in Elder Breast Cancer Patients With Lymph Node Metastasis nanRECRUITING
Quality Of Life While Receiving Faslodex nanCOMPLETED
PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS nanRECRUITING
Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and Lichen Sclerosus nanCOMPLETED
Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PGR binder may also engage these)

ProteinNameSimilarity
A7X8B3 1.000 A7X8B3 →
A7X8C9 1.000 A7X8C9 →
A7X8B5 1.000 A7X8B5 →
A7X8B7 1.000 A7X8B7 →
A7X8C4 1.000 A7X8C4 →
A7XW25 1.000 A7XW25 →
P06186 1.000 P06186 →
Q00175 1.000 Q00175 →
A7XW20 1.000 A7XW20 →
A7XW16 1.000 A7XW16 →
A7X8C7 1.000 A7X8C7 →
A7X8D4 1.000 A7X8D4 →
Q63449 1.000 Q63449 →
A7X8B9 1.000 A7X8B9 →
A7X8C2 1.000 A7X8C2 →
A7X8D2 0.999 A7X8D2 →
O97952 0.999 O97952 →
O97776 0.999 O97776 →
P07812 0.999 P07812 →
P19091 0.998 P19091 →
O97960 0.997 O97960 →
Q9GKL7 0.997 Q9GKL7 →
O97775 0.997 O97775 →
Q6QT55 0.997 Q6QT55 →
Q9TT90 0.996 Q9TT90 →
Q9GLW0 0.996 Q9GLW0 →
Q2VWA4 0.995 Q2VWA4 →
TET3 Methylcytosine dioxygenase TET3 0.995 landscape →
Q8MIK0 0.994 Q8MIK0 →
O14512 0.994 O14512 →